Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
about
Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus InfectionHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionHepatitis C.Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with menHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsMany hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIVDevelopment and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM).HCV and HIV co-infection: mechanisms and management.Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysisSpontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men.Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control StudyThe Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Hepatitis C Screening in People With Human Immunodeficiency Virus: Lessons Learned From Syphilis ScreeningCan Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights.Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainInterferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.After the cure: management of HCV after achievement of SVR.Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles.Acute hepatitis C: management in the rapidly evolving world of HCV.Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.HIV-hepatitis C virus co-infection in the era of direct-acting antivirals.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Reply: To PMID 24797101.Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.HCV reinfection incidence among individuals treated for recent infection.Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.In Vitro Study on Anti-Hepatitis C Virus Activity of Spatholobus suberectus Dunn.
P2860
Q26776408-4ED668C4-A959-4965-B01F-F4A2AA499558Q26798469-ABD01CD7-205D-45B8-8936-C61FC8D0C44FQ26801456-F493CCE2-F6B0-424A-835E-ECFDBAD42436Q28084654-36429C97-9D83-482F-9B94-5D24C735B978Q28088300-D0267F5D-A296-4E2C-AE50-4668D93557DEQ28652352-283E4B26-1ADA-47BE-B78D-F2E97C8F4111Q30884457-31D4A0BD-04FA-4770-B9A2-E54F8BBCD6B4Q33589224-EBD21445-6C9F-4BB2-A253-3655AB05FFE7Q33822918-EC3A97A7-FEE4-48A8-8072-FAB91693DEEEQ35090634-E6D2F5CA-27B8-418B-88BF-3A98E8061E1CQ36096436-E97CA0CF-5788-4F5E-A6C7-C24F4153E360Q36120059-617A82AD-B231-4822-86AE-018F214B3526Q36123263-FECF3912-D1F2-4091-B0B5-9D82BE25E7FAQ36141258-D033D943-F7EC-4C40-A7EE-5D9BFB7FB932Q36334818-F56A0916-ABF2-4A72-844C-DF9B30FE92B0Q36382060-D1FB66E1-F726-4BF6-AE18-497D66B6AA26Q36575314-101016DF-960B-4F49-AC57-F4A7F1AFCC15Q36783221-E905F8E9-2F70-4876-82BE-A3AFF052F0B2Q37055228-E09935ED-A6A4-4C79-A1D7-C53B5926C1E9Q37098390-D26540BE-0609-451B-AC53-D3BB16D4EA49Q37327979-D24F0DE2-1AFB-4F6F-AF49-9C6647941F3EQ37354049-96C9CF1E-B72F-42D0-A093-670DD885E433Q37461905-31DD455B-441A-45F8-863B-ECD70F4435F5Q38161848-2693135A-B8DB-405A-A537-F553C7A1BD8CQ38177972-28641584-1FAA-4B74-9898-0CAD95694825Q38183312-E5FCF5B4-B43F-4E39-9FDC-62984E75D6C8Q38192047-C65FA136-ABCA-4A8D-A879-6F7A03E9ECD9Q38195262-B4EDDBA0-3A5E-4C93-B7F5-ECDC1D5386CCQ38226460-DDB03A94-42D8-4FA1-8064-3908D4301FD4Q38573508-BDDA026E-9C4B-4A2E-B604-092685F8911AQ38635796-4802B36B-0C1B-4071-B6DF-DCFBDCE56AC9Q38692113-9CAC9D93-D5F7-4AB2-841F-4BADEC2E4420Q38769157-92568436-ED69-4890-A55D-72A2FD38975BQ38893104-6235E0B9-C4D4-41D7-BFD8-5FBB5D17E44AQ39909657-2B3FCD5B-D97A-4263-AE20-7AFC2D8F8285Q40153096-CC254028-D06D-4BBB-8BA1-C7A1FEFAE6A8Q40229182-DC17E564-035C-49A2-9EBB-1CD1EBE4313BQ40393982-DE13858D-2C89-496E-9447-3F1BED09DFF9Q40483611-56D8DD23-7A60-4DC0-A868-E7C246479B17Q40501654-3C2DACA0-087A-4D6D-83B5-F0FEFA17547E
P2860
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@ast
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@en
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@nl
type
label
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@ast
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@en
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@nl
prefLabel
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@ast
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@en
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@nl
P2093
P1433
P1476
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.
@en
P2093
Brian G Gazzard
Emma E Page
Mark Nelson
Natasha K Martin
Rhiannon Everett
Thomas C S Martin
P304
P356
10.1097/QAD.0B013E32836381CC
P407
P577
2013-10-01T00:00:00Z